![](/img/cover-not-exists.png)
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
Gianni, Luca, Bisagni, Giancarlo, Colleoni, Marco, Del Mastro, Lucia, Zamagni, Claudio, Mansutti, Mauro, Zambetti, Milvia, Frassoldati, Antonio, De Fato, Raffaella, Valagussa, Pinuccia, Viale, GiuseppLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(18)30001-9
Date:
January, 2018
File:
PDF, 982 KB
english, 2018